Modulation of Host Immunity by Human Respiratory Syncytial Virus Virulence Factors: A Synergic Inhibition of Both Innate and Adaptive Immunity by Canedo-Marroquín, G. et al.
REVIEW
published: 16 August 2017
doi: 10.3389/fcimb.2017.00367
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 1 August 2017 | Volume 7 | Article 367
Edited by:
Steven Varga,
University of Iowa, United States
Reviewed by:
Michael Teng,
University of South Florida,
United States
Nathalie Grandvaux,





Received: 09 May 2017
Accepted: 31 July 2017
Published: 16 August 2017
Citation:
Canedo-Marroquín G,
Acevedo-Acevedo O, Rey-Jurado E,
Saavedra JM, Lay MK, Bueno SM,
Riedel CA and Kalergis AM (2017)
Modulation of Host Immunity by
Human Respiratory Syncytial Virus
Virulence Factors: A Synergic
Inhibition of Both Innate and Adaptive
Immunity.
Front. Cell. Infect. Microbiol. 7:367.
doi: 10.3389/fcimb.2017.00367
Modulation of Host Immunity by
Human Respiratory Syncytial Virus
Virulence Factors: A Synergic
Inhibition of Both Innate and
Adaptive Immunity
Gisela Canedo-Marroquín 1, Orlando Acevedo-Acevedo 1, Emma Rey-Jurado 1,
Juan M. Saavedra 1, Margarita K. Lay 1, 2, Susan M. Bueno 1, Claudia A. Riedel 3 and
Alexis M. Kalergis 1, 4*
1Millennium Institute on Immunology and Immunotherapy, Departamento de Genética Molecular y Microbiología, Facultad de
Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile, 2Departamento de Biotecnología, Facultad de
Ciencias del Mar y Recursos Biológicos, Universidad de Antofagasta, Antofagasta, Chile, 3Departamento de Ciencias
Biológicas, Facultad de Ciencias Biológicas y Medicina, Universidad Andres Bello, Millennium Institute on Immunology and
Immunotherapy, Santiago, Chile, 4Departamento de Endocrinología, Facultad de Medicina, Pontificia Universidad Católica de
Chile, Santiago, Chile
The Human Respiratory Syncytial Virus (hRSV) is a major cause of acute lower respiratory
tract infections (ARTIs) and high rates of hospitalizations in children and in the elderly
worldwide. Symptoms of hRSV infection include bronchiolitis and pneumonia. The
lung pathology observed during hRSV infection is due in part to an exacerbated host
immune response, characterized by immune cell infiltration to the lungs. HRSV is an
enveloped virus, a member of the Pneumoviridae family, with a non-segmented genome
and negative polarity-single RNA that contains 10 genes encoding for 11 proteins.
These include the Fusion protein (F), the Glycoprotein (G), and the Small Hydrophobic
(SH) protein, which are located on the virus surface. In addition, the Nucleoprotein
(N), Phosphoprotein (P) large polymerase protein (L) part of the RNA-dependent RNA
polymerase complex, the M2-1 protein as a transcription elongation factor, the M2-2
protein as a regulator of viral transcription and (M) protein all of which locate inside
the virion. Apart from the structural proteins, the hRSV genome encodes for the
non-structural 1 and 2 proteins (NS1 and NS2). HRSV has developed different strategies
to evade the host immunity by means of the function of some of these proteins that work
as virulence factors to improve the infection in the lung tissue. Also, hRSV NS-1 and
NS-2 proteins have been shown to inhibit the activation of the type I interferon response.
Furthermore, the hRSV nucleoprotein has been shown to inhibit the immunological
synapsis between the dendritic cells and T cells during infection, resulting in an inefficient
T cell activation. Here, we discuss the hRSV virulence factors and the host immunological
features raised during infection with this virus.
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INTRODUCTION
The human Respiratory Syncytial Virus (hRSV) is one of the
most relevant respiratory pathogen affecting infants and the
elderly around the world (Lofland et al., 2000; Falsey et al.,
2005). Importantly, hRSV infection is considered the major cause
worldwide for outpatient visits, hospitalization, and morbidity
in children under 5 years of age, during cold seasons (Nair
et al., 2010; Lambert et al., 2014; Griffiths et al., 2017). It is
estimated that 100% of children at age of 2 have been already
infected with hRSV and ∼2% of them were hospitalized due to
this viral infection (Glezen et al., 1986; Hall, 2001; Deshpande
and Northern, 2003). HRSV induces acute lower respiratory
tract infections (ALRTIs) with a variety of manifestations,
including pneumonia and bronchiolitis, which are accompanied
by other symptoms, such as wheezing, cough and respiratory
distress (Hall, 2001; Openshaw and Tregoning, 2005). The
pulmonary pathology caused by hRSV involves the generation
of immunological hyper-responsiveness in the airways (Jafri
et al., 2004; Bueno et al., 2008). It has been proposed that an
early exposition to hRSV could be associated with reinfections
(Dakhama et al., 2005), susceptibility to allergy (Sigurs et al.,
2010), recurrent wheezing episodes, also called post-bronchiolitis
wheeze (PBW) (Pullan and Hey, 1982; Sigurs et al., 2010), and
development of asthma (Pullan and Hey, 1982; Siegle et al.,
2010; Wu and Hartert, 2011). Similar to other viruses, hRSV
has developed various strategies to avoid the clearance by the
host immune system to achieve efficiently spreading through
pulmonary epithelial cells (Iannello et al., 2006). The hRSV
genome encodes proteins that are fundamental to enter and to
infect the host, some of them can be considered as virulence
factors (Espinoza et al., 2014). These proteins contribute to
the virus strategies to evade the host immune system, in turn
improving the viral fitness. In this review article, we discuss
the influence of these hRSV proteins in counteracting the host
immune response.
STRUCTURAL FEATURES OF HRSV
HRSV is an enveloped virus, recently characterized as a member
of the Pneumoviridae family (Afonso et al., 2016) with a non-
segmented genome and negative polarity-single stranded RNA.
The 15,200 bp length genome contains 10 genes (3′-NS1-NS2-
N-P-M-SH-F-G-M2-L-5′). These genes encode 11 proteins that
include from the 3′ to 5′ ends: the non-structural proteins 1
and 2 (NS1 and NS2); the nucleocapsid protein, also known
as nucleoprotein (N); another nucleocapsid protein, named
the phosphoprotein (P); the matrix protein (M); the small
hydrophobic protein (SH); the glycoprotein (G); and the fusion
protein (F). In addition, the M2 gene contains two open reading
frames, encoding either the M2-1, which is a transcription
elongation factor, or the M2-2, which is a regulator of the
viral transcription. Finally, the hRSV L gene encodes for the
nucleocapsid protein RNA polymerase. Therefore, the hRSV
genome encodes nine structural and two non-structural proteins
(Collins and Graham, 2008) (Figure 1).
The hRSV non-structural proteins 1 and 2 (NS1 and NS2)
are small proteins composed of ∼140 amino acids each. The
genes encoding for these proteins are located in the three end
region of the hRSV genome. Therefore, the transcription of these
genes occur in the early stages of the infection (Ling et al., 2008,
2009). Furthermore, it has been described that these proteins are
localized in the nuclei and mitochondria of hRSV-infected cells
(Swedan et al., 2011). Importantly, NS1 and NS2 proteins impair
the induction of the interferon α and β (IFN-α/β) pathways,
during the infection of the host (Hastie et al., 2012).
The matrix protein (M) is a non-glycosylated protein that
forms a protein layer under the viral envelope, surrounding
the nucleocapsid, and interacts with the viral membrane. This
protein plays an important role during hRSV replication,
budding and assembly (Ghildyal et al., 2002, 2006). Specifically,
using a chromatography-multiangle laser light scattering
technique, it was found that the M protein is found in a dimeric
form in solution, and it is required for budding and viral release
(Förster et al., 2015). Furthermore, the M protein interacts
directly with the plasma membrane, herein protecting the
genome and their components (Money et al., 2009). Both the
N and the P, which are nucleocapsid proteins, are essentials
for the replication and transcription activities. Indeed, the
N protein is a 43 KDa protein (Cannon, 1987) that contains
an helical structure bound to the ribonucleoprotein complex.
Furthermore, the N protein covers the viral RNA, during
transcription and replication of the virus in the host cell, thereby
contributing in protecting it from the antiviral response, and
in preserving the structure of the ribonucleoprotein complex
(Bhella et al., 2002; Tawar et al., 2009). In addition, the N
protein has been shown to impair the immunological synapse
between dendritic cells and T cells (Cespedes et al., 2014).
Interestingly, the N protein was found to be present on the
surface of hRSV-infected cells (Cespedes et al., 2014). However,
further studies are required to elucidate the exact mechanism
in how this event occur. On the other hand, the P gene encodes
for a protein of 241 amino acids, which is a co-factor of the
hRSV L-polymerase. Moreover, it binds the N protein with
the helical structure, forming a specific P-N complex (Bakker
et al., 2013). Besides, the P protein can work as a chaperone,
preventing the interaction of the newly synthesized unassembled
N protein with the viral RNA, during the encapsidation process
of the new hRSV virions in infected cells. In addition, the
P protein participates in hRSV replication and transcription
events (Galloux et al., 2012, 2015). On the other hand, the
L gene contains a highly conserved sequence that encodes
for a 2,165 amino acid long protein that works as the major
catalytic subunit of the RNA-dependent RNA polymerase
(RdRp) complex (Fix et al., 2011). Also, the M2-1 and the
M2-2 proteins participate and regulate the hRSV transcription
and replication processes. While the M2-1 along with the P
protein regulate the transcription of mRNAs, contributing to
the processivity of the L-polymerase; the M2-2 protein mediates
the transition from transcription to replication (Collins et al.,
1995; Bermingham and Collins, 1999; Cheng et al., 2005).
Recently, it was shown that the M2-1 is located between the
ribonucleoprotein complex and the M protein in the viral
particle (Kiss et al., 2014).
The F protein is a transmembrane protein composed of
574 amino acids (McLellan et al., 2013) that is required
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FIGURE 1 | (A) Representation of Human Respiratory Syncytial Virus (hRSV) structure and the viral proteins. hRSV proteins have external proteins such as: Fusion
protein, Glycoprotein, and Small Hydrophobic protein. The internal proteins are: Matrix protein and proteins belonging to the nucleocapsid, which include the
Nucleoprotein, the Phosphoprotein, and the Large polymerase protein. (B) HRSV genome harboring the 10 genes, in a 3′–5′ sense, indicating the protein that encode.
for hRSV fusion and entry to the host cell. Further, the
F protein promotes viral fusion to the host cell membrane
and formation of epithelial cell-cell syncytium in the infected
airway tissue (Openshaw and Tregoning, 2005). Such function
has been previously suggested through the binding of two
specific inhibitors of hRSV F protein (CL-309623 and RFI-
641), herein preventing the entry and fusion of the virus
to the Vero cells (Razinkov et al., 2002). Another study, in
which a mutant hRSV strain, lacking the glycoprotein (G) and
SH genes, was studied and showed that the F protein favors
the post-attachment rate entry in the Hep-2 cells. Thus, the
presence of F protein is required for hRSV entry into the
host cell (Techaarpornkul et al., 2001). Furthermore, it has also
been reported that the F protein interacts with nucleolin, an
ubiquitous host receptor (Losfeld et al., 2009; Tayyari et al.,
2011). Specifically, co-immunoprecipitation assays, using human
airway epithelial cell lysates, showed that the nucleolin interacted
with the F protein (Tayyari et al., 2011). The requirement of
this receptor for the entry of hRSV to cells was demonstrated
by applying a treatment with an anti-nucleolin antibody, which
caused a poor co-localization of the virus on the cell surface
and decreased hRSV infection (Tayyari et al., 2011). Recently,
it was found that the hRSV entry is mediated by the Rab5
macropinosomes, since Rab5-deficient HeLa cells displayed
lower levels of hRSV infection, as compared to wild type cells
(Tayyari et al., 2011). Further, such hRSV entry mechanism
was demonstrated to be pH, clathrin and dynamin independent
(Tayyari et al., 2011). Moreover, it was shown that hRSV
transient macropinocytosis requires two cleavages of the F
protein (Krzyzaniak et al., 2013). Nevertheless, this notion is at
variance with a previous study, proposing that the hRSV entry
takes place due to a clathrin-mediated endocytosis (Kolokoltsov
et al., 2007).
The hRSV G is a glycosylated transmembrane protein of
80 kDa (Melero et al., 1997; McLellan et al., 2013). Moreover,
a soluble form of the G protein, lacking the cytoplasmatic
and transmembrane domains, has been described to work as a
decoy for neutralizing antibodies, thereby avoiding the antiviral
response of the host (Bukreyev et al., 2008, 2012). Additionally,
the G protein, due to its sequence diversity, has been employed as
a molecular marker to discriminate between the hRSV subtypes
A and B (Anderson et al., 1985; Mufson et al., 1985). Importantly,
the G gene encodes for a viral transmembrane protein that is
important for the hRSV attachment to the host cell (Levine
et al., 1987). In fact, the attachment function of the G protein
was first identified in HeLa cell monolayers (Levine et al.,
1987). These cells were treated with anti-G and then challenged
with a radiolabeled hRSV. As a result, an inhibition of viral
particle attachment to the HeLa cells was observed (Levine
et al., 1987). Initially, it was thought that the G protein binds
to the heparan sulfate on the extracellular matrix of the host
cells (Feldman et al., 1999). However, a study in human airway
epithelium (HAE) showed that CX3R1, a receptor on ciliated
cells, is pivotal for the G protein-mediated attachment of viral
particles (Johnson et al., 2015). Indeed, a decreased of hRSV
infection was observed with the neutralization of CX3R1 by
using two specific monoclonal antibodies (Johnson et al., 2015).
The molecular explanation for this specific attachment of the
virus with CX3R1, derives from the similarity of the G protein
to CX3CL1, a chemokine produced by immune cells, such as
macrophages and dendritic cells (Papadopoulos et al., 1999). The
sequence similarity between the G glycoprotein and the CX3CL1
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molecule locates at the chemokine-like motif, composed of 4
amino acids, at the positions 182–186 of the G protein conserved
region (Tripp et al., 2001; Harcourt et al., 2006).
Moreover, the SH gene encodes a 64 amino acid protein for
hRSV serotype A and a 65 amino acid protein for the hRSV
serotype B (Collins and Mottet, 1993). The SH glycoprotein is
neither required for the entry to the host cells nor needed for
viral RNA replication (Bukreyev et al., 1997; Techaarpornkul
et al., 2001). However, several studies that evaluated mutant
hRSV strains that lack the SH gene, have shown an attenuation
in the virulence (Karron et al., 1997; Techaarpornkul et al., 2001;
Rixon et al., 2004). Also, in other studies the hRSV SH protein is
suggested to prevent apoptosis in hRSV-infected cells (Lin et al.,
2003; Fuentes et al., 2007). Specifically, these studies demonstrate
that SH protein has an important role in hRSV infection, since
SH prolongs the cellular life, allowing a continuous virion
production. Recently, the SH pentameric model shows that the
structure anchored in a lipid bilayer, display N-terminal and
C-terminal ends, which are composed by random coil and β-
sheet structures, conforming a pore structure (Araujo et al.,
2016). Those regions are suggested to be important channels for
hRSV pathogenesis. Thereby, it may be a mechanism to inhibit
ligand-mediated apoptosis in the hRSV-infected cells.
EFFECT OF HRSV PROTEINS IN THE
INNATE IMMUNE RESPONSE: HRSV
RECOGNITION BY THE HOST AND
INTERFERENCE OF THE IFN PATHWAY
Different cellular receptors recognize hRSV molecular patterns,
including Toll-like receptors (TLR), trigger an innate immune
response. Interestingly, an interaction between the F protein and
the TLR-4 activate this receptor, herein initiating an antiviral
immune response (Rallabhandi et al., 2012). Along these lines,
an hRSV persistent infection was found in TLR-4 deficient mice,
as compared to wild-type mice (Kurt-Jones et al., 2000). Thus,
TLR-4 activation is clearly important for an appropriate antiviral
response, avoiding a persistent hRSV infection (Kurt-Jones et al.,
2000).
The type I IFN response is key for the antiviral response
(García-Sastre and Biron, 2006). In this regard, NS1 and NS2
proteins hamper the IFN-α/β production during hRSV infection
(Spann et al., 2004, 2005). The function of these proteins was
discovered in human airway epithelial cells (A549) and human
peripheral blood monocyte cell derived-macrophages, which
were infected with the hRSV A2 strain and the recombinant
hRSV mutants, lacking the NS1 gene (1NS1), the NS2 gene
(1NS2) and both NS1 and NS2 (1NS1/NS2). Specifically, in this
study, the authors observed an increase in IFN-α/β production in
cultures infected with the1NS1/NS2 hRSV strains (Spann et al.,
2004). Furthermore, it has been reported that the NS1 protein
co-localizes with a critical molecule of the type I IFN pathway,
the mitochondrial signaling protein (MAVS), thus inhibiting the
phosphorylation of the interferon regulatory factor 3 (IRF-3)
(Boyapalle et al., 2012). Likewise, NS1 can bind directly to IRF-
3 and the CREB binding protein (CBP), both transcriptional
activators of the type I IFN system. Therefore, it is thought that
those interactions reduce the binding between IRF-3 and the
IFN-β promoter, decreasing the antiviral cascade activation (Ren
et al., 2011). Similarly, NS2 interferes with the activation of the
IRF-3 by binding to RIG-I (Ling et al., 2009). In addition, NS1
has been shown to promote the proteosomal degradation of 2′–
5′Oligoadenylate synthetase-like protein (OASL), which is a type
I IFN-inducible effector molecule that control viral replication
(Dhar et al., 2015). Moreover, it was suggested that the NS1
protein increases miR-29a levels, which inhibits the expression
of the IFNα/β receptor (IFNAR1) that is essential for the type
I IFN function (Zhang et al., 2016). Following the IFNAR1
mRNA interference by hRSV, the NS1 protein suppresses the
expression of miR-24, by producing the Kruppel-like factor 6
(KLF6). Specifically, KLF6 induces the production of TGF-β,
which in turn inhibits miR-24 and thought to cause cell arrest,
reducing apoptosis and increasing viral replication (Bakre et al.,
2015). This notion is supported by previous studies showing that
NS1 and NS2 were involved in the inhibition of cell apoptosis in
the early stages of the hRSV infection (Bitko et al., 2007). Thus,
through the action of NS proteins, hRSV can inhibit apoptosis
to persist for longer periods in the host and avoid the innate
immune response.
Additionally, it has recently been shown that both the NS1 and
NS2 proteins induce the proteosomal degradation of the signal
transducer and activator of transcription 2 (STAT2) (Whelan
et al., 2016). As a result, the host antiviral response mediated
by the type IFN I pathway is largely impaired, as well as viral
clearance (Lo et al., 2005; Ramaswamy et al., 2006; Elliott et al.,
2007; Jie et al., 2011). Moreover, it was reported that BALB/c
mice infected with recombinant hRSV lacking the NS genes
(hRSV1NS1, hRSV1NS2, and hRSV1NS1/NS2) showed an
increased frequency of cytotoxic T cells (CTLs) as compared
to mice infected with wild-type hRSV, which are susceptible to
suppression of the type I IFN response (Kotelkin et al., 2006).
Therefore, hRSV NS proteins are critical for hRSV pathogenesis
not only by inhibiting the type I IFN pathway but also by
impairing the proliferation of host CTLs. The capacity of hRSV
to inhibit this process is likely to contribute to the frequent
re-infections caused by hRSV throughout life.
Another important protein that affects the ability of the innate
immune response to recognize and respond to an hRSV infection
is the G protein, specifically a CX3C motif present in this protein
(Chirkova et al., 2013, 2015). A recent study in human airway
epithelial cells infected with hRSV (with an intact CX3C motif)
or with a strain with a mutant motif (CX4C) produced lower
levels of IFN-γ and IFN-λ, as compared to IFN-α, suggesting
that CX3CR is playing a suppressor role in the IFN pathways
(Chirkova et al., 2013). The molecular similarity between the
G protein and the CX3CR1, as above mentioned, impairs the
binding of the CX3CL1 chemokine to the CX3CR1 receptor,
promoting hRSV infection in the host (Chirkova et al., 2013,
2015). Further, it has been evidenced the presence of CX3CR1
not only in airway epithelial cells, but also in NK and cytotoxic
T cells (Mionnet et al., 2010; Johnson et al., 2015). Thus, the G
protein of hRSV also contributes to impairing the host immune
response and promotes viral dissemination.
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Apart from triggering IFN responses, hRSV activates the
inflammasome through the activity of the viral SH protein.
It was observed that the inflammasome activation and IL-1β
secretion in hRSV-infected primary human lung epithelial cells
was higher than in cells infected with a recombinant hRSV,
lacking the SH protein (hRSV1SH) (Triantafilou et al., 2013;
Russell et al., 2015). Also, the hRSV-infected cells express caspase
1, a pivotal element in the inflammasome activation (Triantafilou
et al., 2013). In addition, a decrease in IL-1β production was
found in lung epithelial cells, treated with ion channels inhibitors
(hexamethylene amiloride, EIPA and benzamil) upon hRSV
infection (Triantafilou et al., 2013). Taken together, these data
suggest that hRSV SH protein is involved in the assembly of
ion channels required for the inflammasome activation (Gan
et al., 2008, 2012; Triantafilou et al., 2013). However, additional
research is needed to elucidate the mechanisms employed by the
SH protein to impair the proper function of the host immune
system.
EFFECT OF HRSV PROTEINS IN THE
ADAPTIVE IMMUNE RESPONSE:
INHIBITION OF THE IMMUNOLOGICAL
SYNAPSE AND THE T CELL ACTIVATION
Antigen-presenting cells (APCs) play an essential role during
the infection, as these cells can present peptide-, lipid-, and
vitamin B precursor-based antigens (Ags) in the context of
the major histocompatibility complex (MHC) or MHC-like
molecules, respectively (Beckman et al., 1994; Germain, 1994;
Kjer-Nielsen et al., 2012). The pMHC complexes on the surface
of APCs are recognized by the T cell receptor (TCR), which
is an antigen-specific molecule expressed on the surface of T
cells. Thus, the naïve T cell becomes activated contributing to
the initiation of the adaptive immune response against pathogens
(Brownlie and Zamoyska, 2013). Such interaction occurs through
the variable regions of the TCR α and β chains. At the interface,
between pMHC complexes and the T cell receptor, there are
three hyper variable loops, termed complementarity-determining
regions (CDRs) that make contact with antigens (Hughes et al.,
2003). Effective interaction between TCR and pMHC molecules
triggers a tyrosine phosphorylation cascade inside of the T-
cell membrane, as well the activation of multiple signaling
pathways (Janeway et al., 2001). The adaptive immune response
complex processes, such as the T cell proliferation, require of
the TCR engagement and triggering of the respective signaling
cascades, which occur within minutes or hours. However, the
sustained TCR engagement with its cognate antigen that takes
place is constrained by many barriers. As a first point, TCR
engagement is limited by the small size of the TCR and MHC
molecules, surrounded with large and abundant glycoproteins
like CD43 andCD45, that imposes steric hindrance to TCR-MHC
interaction (Cyster et al., 1991; McCall et al., 1992). On the other
hand, the affinity of TCR for peptide-loaded MHC molecules is
low (<100 µM) (Davis et al., 1998; Knapp et al., 2015) and the
continuous movement of T cells makes sustained recognition of
pMHCs by TCRs a challenging process.
Different studies related to the interaction between pMHCs
with TCRs have revealed the formation of a specialized supra
molecular structure, termed the immunological synapse (IS). The
formation of this interaction requires the engagement of TCR
by pMHCs. This process triggers the rearrangement of a variety
of receptor-ligand pairs. Firstly, the interaction between LFA-1
and ICAM-1 proteins anchors the central region of the nascent
IS (Grakoui et al., 2015). This interaction facilitates cytoskeletal
movements that ultimately can position peripheral TCRs close
to their cognates ligands. This rearrangement produces TCR-
enriched migrating regions known as TCR microclusters. In
the subsequent steps, the TCR microclusters are arranged in
the central region of the IS in a domain known as the central
supramolecular activation cluster (cSMAC) (Grakoui et al., 1999;
Varma et al., 2006). Concomitantly, ICAM-1-LFA1 pairs are
positioned into a peripheral adhesion domain or pSMAC, leading
to assembly of the IS (Grakoui et al., 1999).
As the assembly of the IS is a pivotal requirement for the
establishment of proper T-cell responses and the development
of the T-cell memory, many pathogens such as viruses have
developed virulence mechanisms to impair the assembly of the
IS and the initiation of the adaptive immunity (Muller et al.,
2006; Thoulouze et al., 2006). Specifically, our research group
has studied that hRSV infection promotes DCs maturation
and the secretion of IL-6 and IL-10. However, these APCs are
impaired in their ability to induce T cell activation despite the
fact that these cells present either allo- cognate or superantigens
to T lymphocytes (Gonzalez et al., 2008). Remarkably, hRSV
suppression of T cell activation by using DCs in vitro was not
mediated by inhibitory soluble factors secreted by these APCs. By
contrast, it was found that stimulating cytokines such as IL-2 were
increased in the supernatants obtained from hRSV-infected DCs.
Interestingly, human monocyte-derived myeloid dendritic
cells infected with recombinant hRSV, lacking the NS genes
(hRSV1NS1 and hRSV1NS2), showed a significantly increased
expression of maturation markers, as compared to wild-
type hRSV-infected cells (Munir et al., 2008). Furthermore,
virus lacking the NS1 protein (1NS1) induced an increased
proliferation and activation of CD8+ T cell specific to epithelial
cells (Munir et al., 2011). These results suggest that the NS genes
modulate the maturation of DCs, reduce antigen presentation
and the T cell activation, impairing key components of the host
immune response against hRSV infection.
Remarkably, it has been suggested that hRSV proteins impair
the assembly of the IS between T cells and DCs (Gonzalez
et al., 2008). As supporting evidence for this hypothesis, it was
found that polarization of the Golgi apparatus was reduced
to a background frequency in OT-II T cells pulsed with OVA
peptide and co-cultured with hRSV-infected DCs. Thus, the
impairment of the T cell function by hRSV infection seems
to be a process that requires cell-to-cell contact. Moreover, it
was shown that impairment of the T cell function by hRSV
could be a consequence of an anergic-like phenotype of T-
lymphocytes triggered by a dysfunctional IS assembly between
T cells and DCs, since T cells co-cultured with hRSV-infected
DCs remained irresponsive to a strong activating stimulus, such
as of an anti-CD3ε antibody treatment (Gonzalez et al., 2008).
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We have also recently found that the hRSV-N could be involved
in inhibiting T-cell activation during infection (Cespedes et al.,
2014). Indeed, experiments on supported lipid bilayers (SLBs),
loaded with pMHC complexes, showed that the hRSV N protein
prevented the IS assembly in both naive CD4+ T cells and, to
a lesser extent, antigen-experienced T-cells. These results are
attributable to an increased sensitivity of the antigen-experienced
T-cell to pMHCs, as the frequencies of the mature IS in antigen-
experienced cells were significantly increased compared to those
observed in naïve T-cells (Cespedes et al., 2014). This result,
could be explained because antigen experienced T-cells can form
large sizes of TCR oligomers, which showed increased pMHC
sensitivity compared to shorter TCR oligomers found in naïve
CD4+ T cells (Kumar et al., 2011).
As a general point, inhibition of the IS assembly by the
action of the N protein, observed in this work, was in part
attributable to diminished TCR signaling and pMHC clustering
at the T-cell- bilayer interface. This criterion was not matched
by proteins that do not inhibit the IS, including hRSV M2-1 and
GFP. Interestingly, it was found that soluble N protein does not
colocalize with pMHCs loaded on SLBs. Instead, the N protein
interacts in trans with the TCR molecules of T-lymphocytes, as
TCR signal colocalizes with fluorescent-tagged N proteins.
Since the soluble N protein colocalizes with the TCR, it was
hypothesized that hydrophobic residues within the N protein
could transiently interact with the phospholipid bilayer after
reaching the membrane of infected cells. In this sense, this
study also demonstrated that N-protein, which is associated with
viral RNA, could be expressed on the surface of viral particles
as an early event (1 h) post-infection (pi). Importantly, the
results obtained also suggest that virus attachment and virus-cell
fusion to target cells would be sufficient to deliver the N protein
on the APCs surface to impair the IS (Cespedes et al., 2014).
However, the specific mechanisms accounting for the transport
of the N protein to the cell surface are not well-understood.
Nevertheless, we suggest that the N protein could interact with
the Golgi apparatus or lysosomal membranes in the cytosol of
infected cells (Figure 2). These notions are supported by the
observations that at 24 h pi, a time point in which infected
cells expressed mostly soluble N-protein (Fearns et al., 1997), the
hRSV-N colocalizes with a membrane-anchored Golgi enzyme
GALNT2+ structures. Further, it was shown that treatment
with Brefeldin-A, an inhibitor of protein transport from the
endoplasmic reticulum to the Golgi apparatus (Klausner et al.,
1992), reduces the amount of N protein on the surface of infected
cells and triggers its accumulation in GALNT2+ and Lysosomal-
associated membrane protein 1 (LAMP1+) compartments.
Therefore, both trans-Golgi and lysosomal exocytic pathway
could be involved in the transport of the N protein to the cell
surface (Cespedes et al., 2014) (Figure 2).
CONCLUDING REMARKS
HRSV is one of the major respiratory pathogens causing a
major health burden worldwide. This virus can produce several
reinfections throughout life even can leave sequelae, such as
asthma and respiratory allergies. Research on hRSV has taken
FIGURE 2 | Proposed model for the inhibition of the IS assembly between
Antigen Presenting Cells (APCs) and T lymphocytes, triggered by N protein. At
an earlier infection stage point (such as 24 hpi), attachment and fusion of
hRSV to APC membranes is enough to deliver N protein in the cytosol of an
infected APC. Subsequently the N protein could be transported to the cell
surface through the lysosomal exocytic pathway (LAMP1+ structures, in
yellow) or the trans-Golgi network (GALNT2+ structures shown in blue). As the
N protein is expressed on the surface of APC, the clustering of pMHC
molecules is inhibited, as well as, the IS assembly. Based on primary amino
acidic sequence analysis, we propose that a hydrophobic-rich residue region
of the hRSV N could serve to anchor the N protein on the APC surface
membrane (inset). Numbers indicate the exact positions in where this region is
localized in the N protein, according to TMHMM Server v. 2.0 analysis.
more than five decades, however, up to date, there are no
licensed vaccines available to combat this virus. Currently, only
an expensive prophylactic treatment is available based on the
administration of specific monoclonal antibodies against the F
protein (e.g., Palivizumab). HRSV has co-evolved with humans
during years and as a result, different hRSV genes are considered
as virulence factors, which contribute to hRSV survival and
dissemination in the host. Furthermore, some of these genes have
the capacity to interfere with the assembly of the IS, interfering
with the establishment of a proper T cell memory, favoring herein
hRSV reinfections.
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